- cafead   Feb 06, 2025 at 12:02: PM
via
article source
- Adjusted EPS of $1.67 beat expectations of $1.46.
- Revenue rose to $12.3 billion, exceeding estimates of $11.57 billion.
- The growth portfolio of drugs saw a 21% revenue increase, driven by Reblozyl, Breyanzi, and Camzyos.
article source